Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Trimmed by Everhart Financial Group Inc.

Everhart Financial Group Inc. lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 22.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,656 shares of the pharmaceutical company’s stock after selling 480 shares during the quarter. Everhart Financial Group Inc.’s holdings in Vertex Pharmaceuticals were worth $667,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Northwest Investment Counselors LLC purchased a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $25,000. Dunhill Financial LLC boosted its position in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 24 shares during the period. Highline Wealth Partners LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $27,000. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $33,000. Finally, Brown Lisle Cummings Inc. acquired a new stake in Vertex Pharmaceuticals during the 4th quarter worth about $30,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

VRTX has been the subject of a number of research reports. Canaccord Genuity Group upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and raised their price objective for the stock from $408.00 to $424.00 in a research report on Tuesday, February 11th. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Barclays raised their price objective on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 11th. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Citigroup assumed coverage on Vertex Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $575.00 price target for the company. Ten investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $505.57.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $459.00 on Monday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $435.69 and its two-hundred day moving average is $461.24. The company has a market cap of $118.21 billion, a P/E ratio of -230.65, a P/E/G ratio of 1.80 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.94 EPS for the current year.

Insider Activity

In other news, EVP Ourania Tatsis sold 310 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the sale, the executive vice president now directly owns 64,021 shares in the company, valued at approximately $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.